Sentinel surveillance and universal PCR screening detect local Mycoplasma pneumoniae epidemic

The first signs of the 2024 Mycoplasma pneumoniae wave in Nara, Japan, were not caught by the national sentinel surveillance system but by a single hospital running universal PCR tests on every child who walked through its doors with fever or respiratory symptoms. That is the central finding of a new study published in New Microbes and New Infections, which compared how quickly two very different surveillance strategies—universal PCR screening at one medical center and traditional sentinel reporting from five clinics—were able to detect a local epidemic of one of the most important causes of childhood pneumonia.

Researchers at Nara Prefecture General Medical Center (NPGMC) analyzed weekly case counts and PCR positivity rates spanning nearly four years of testing, from November 2020 through September 2024. Their results suggest that in the post-COVID-19 era, when respiratory pathogens are resurfacing in unpredictable patterns, molecular screening may offer public health officials an earlier and more statistically robust warning signal than systems that depend on physicians deciding, case by case, which tests to order.

Mycoplasma pneumoniae is an atypical bacterium without a cell wall, and it is a leading cause of community-acquired pneumonia, particularly among school-aged children and adolescents. It spreads through respiratory droplets in close-contact settings such as classrooms and households, and its epidemics tend to follow cyclical patterns with intervals of several years between major waves. In Japan, cases of MP pneumonia have historically been tracked through a sentinel surveillance system in which designated facilities report clinically diagnosed cases to national authorities. But the system has a blind spot: it does not record how many tests were performed, what type of test was used, or what proportion of tests came back positive. That means the reported numbers can rise simply because physicians are ordering more tests—not necessarily because more people are infected.

The NPGMC team set out to quantify exactly how much that blind spot matters in practice. Since November 2020, the hospital has applied a policy of universal PCR screening, testing all symptomatic patients aged 15 or younger who presented with acute-onset fever or respiratory symptoms. The test used was the FilmArray respiratory panel, a multiplex PCR platform manufactured by bioMérieux that can detect more than a dozen respiratory viruses and bacteria simultaneously from a single specimen. The stated purpose was practical rather than epidemiological: appropriate cohorting of infected patients to prevent hospital-acquired transmission. But the resulting dataset—more than 6,300 tests accumulated over four years—gave researchers an unusually complete picture of pathogen activity in their catchment area, unaffected by the clinical judgment or epidemic awareness of individual physicians.

To determine when the 2024 epidemic actually began, the researchers needed an objective threshold. They turned to historical benchmarks, extracting weekly counts of MP pneumonia per sentinel facility at both the national and Nara prefecture levels between 2014 and 2023. For each benchmark, they calculated the mean weekly count plus three standard deviations—values of 5.8 cases per week nationally and 7.9 cases per week in Nara prefecture—as upper limits beyond which an outbreak could be declared. This approach, a classic method in infectious disease epidemiology, treats ordinary year-to-year fluctuation as noise and flags only statistically unusual surges as signals.

The results revealed a clear time lag between the two systems. At NPGMC, 105 of the 6,301 PCR tests conducted over the study period—1.67 percent—were positive for Mycoplasma pneumoniae. Continuous detection of the bacterium began in week 21 of 2024, and case numbers climbed steadily, crossing the national benchmark threshold in week 27 and the local Nara prefecture threshold in week 29. The five sentinel facilities in the prefecture, by contrast, did not begin to surge until a few weeks later, reaching the national benchmark in week 30 and the prefecture benchmark only in week 39—roughly ten weeks after the PCR signal at the single hospital had already flagged the outbreak.

Perhaps more striking were the results from the positivity rate, a metric the sentinel system cannot collect because it never records the denominator of tests performed. Drawing on Japanese data showing that MP positivity rates remain below 5 percent outside epidemic periods and rise to around 11.8 percent during outbreaks, the researchers set thresholds of 5 percent and 10 percent positivity sustained for two consecutive weeks. The hospital’s PCR data crossed the 5 percent threshold in week 23 and the 10 percent threshold in week 27—both ahead of the absolute case-count signals, and the week-23 positivity signal arriving six weeks before the national sentinel benchmark was breached. Positivity rate, the authors argue, is intrinsically less vulnerable to the artifact of variable testing volume, making it a potentially powerful complement to raw case counts.

The study’s authors are careful to explain why the two systems diverged. Rapid antigen tests and antibody titers, the methods often used in outpatient settings, are less sensitive and less specific than PCR. But the deeper issue is behavioral: physicians tend to order tests for respiratory pathogens based on the local epidemiological situation. In other words, clinicians at sentinel facilities may not have started systematically testing for MP in children with pneumonia until they already recognized that an outbreak was underway—a circularity that inherently delays detection. Universal screening, by contrast, tests everyone regardless of suspicion, breaking that feedback loop and capturing the true beginning of pathogen circulation.

The findings arrive at a moment of renewed global attention to Mycoplasma pneumoniae. Following the relaxation of COVID-19 mitigation measures, multiple countries have reported unusual resurgences of the bacterium, a pattern widely attributed to the accumulation of susceptible children who were never exposed during years of masking, distancing, and school closures. Japan’s own national surveillance registered the 2024 wave against this backdrop, and the Nara experience suggests that PCR-based monitoring could serve as an early-warning instrument for the re-emergence of not just MP but other respiratory pathogens whose epidemiology was disrupted by the pandemic.

The researchers are equally candid about the limitations of their analysis. The two surveillance approaches differed not only in testing modality but in case definitions and testing sites, so direct claims of superiority would be unwarranted. The study was conducted at a single center, and the reliance on weekly absolute case counts proved statistically fragile: adding or subtracting a single case could shift the week in which a threshold was crossed by as much as two weeks in either direction. For example, one additional case would have moved the NPGMC signal to week 27 for the national benchmark and week 29 for the prefecture benchmark, while one fewer case would have delayed both signals by two weeks. This sensitivity raises concerns about false alarms, which is why the authors recommend combining multiple indicators—absolute counts, positivity rates, and potentially other metrics—rather than relying on any single trigger. They also note that both systems counted cases by the date of testing rather than the date of symptom onset, meaning that true epidemic onset may have occurred even earlier than either system detected.

There are also questions of cost and practicality that the study deliberately leaves open. Multiplex PCR panels are substantially more expensive than rapid antigen tests, and whether universal screening of all symptomatic children is cost-effective as a public health strategy—rather than an infection-control convenience—remains to be evaluated. The study measured detection timing only; it did not assess whether earlier detection actually translated into better clinical outcomes or more effective outbreak control. Detecting an epidemic sooner, in other words, is only valuable if the health system is prepared to act on the information, whether through targeted vaccination campaigns where applicable, antimicrobial stewardship, school-based interventions, or public communication.

The researchers did identify one piece of low-hanging fruit for Japanese surveillance policy: the national system could begin collecting testing volumes alongside case counts, enabling positivity rates to be calculated at the population level for the first time. Given that the positivity rate crossed its threshold weeks before any absolute case-count signal in the Nara data, this relatively simple administrative change could meaningfully sharpen the country’s epidemic detection capabilities without requiring any new laboratory infrastructure.

For now, the study stands as a proof of concept that the laboratory can serve as a sentinel. As respiratory pathogens continue to behave unpredictably in the aftermath of the COVID-19 pandemic, the experience in Nara suggests that the most reliable early warning of an emerging outbreak may come not from clinics reporting what they suspect, but from diagnostic platforms reporting everything they find.